Shares of Moderna Inc (NASDAQ:MRNA) continues to move higher in the pre-market on Tuesday after the company announced the news this morning.
Moderna announces that the Phase 2/3 study of its COVID-19 vaccine in adolescents has met its primary immunogenicity endpoint, successfully bridging immune responses to the adult vaccination. Primary endpoint of non-inferior immunogenicity versus the Phase 3 study adult comparator group was met.
No cases of COVID-19 observed after two doses of vaccine using the primary case definition, consistent with a vaccine efficacy of 100%. Safety and tolerability generally consistent with Phase 3 COVE study in adults; no significant safety concerns identified.
The company plans to submit data to regulators globally in early June.
MRNA stock is up by another 2.82% to $168.80 after gaining 1.68% in yesterday’s trading session. The stock has soared 45% since late March and up 188% over the past year.
Biotech, Tech, and Crypto reporter
Anthony Gonzales brings 3 years of experience in helping grassroots, mid-sized organizations and large institutions strengthen their management and resource generating capacities and effectively plan for the future. He is also a mentor and professional advisor to artists working in all disciplines. He is the gold medalist from St. Marco University of Science and Technology in the Bachelors of Financial Management as well.